KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
A phase 2 trial of KC1036, Toripalimab and Cisplatin in oesophageal cancer, run by Beijing Konruns Pharmaceutical Co., Ltd., now recruiting.
Overview
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer is a phase 2 interventional study registered as NCT07481058 by Beijing Konruns Pharmaceutical Co., Ltd., with 60 participants planned, started 2025-12-12 and due to reach its primary completion in 2027-12. Interventions recorded: KC1036, Toripalimab, Paclitaxel and Cisplatin.
Similar pages
not linked directly; found by shared links- TrialA Study of KC1036 in Patients with Advanced Thymic Tumors
Shares Beijing Konruns Pharmaceutical, KC1036 and the tag pipeline.
- TrialA Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
Shares Beijing Konruns Pharmaceutical, KC1036, Oesophageal cancer.
- Trial9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Shares Toripalimab, Cisplatin and the tag pipeline.
- TrialA Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
Shares Toripalimab, Cisplatin and the tag pipeline.
- TrialA Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
Shares Cisplatin, Oesophageal cancer and the tag pipeline.
- TrialSKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
Shares Cisplatin, Oesophageal cancer and the tag pipeline.
- TrialStudy of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
Shares Cisplatin, Oesophageal cancer and the tag pipeline.
- TrialA Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Shares Cisplatin, Oesophageal cancer and the tag pipeline.